LUCY SORTO: Open Payments
NPI 1366056764 · BUFORD, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,575 in 91 payments from 32 companies in 2025. Trend: 2023 $1,869 · 2024 $1,920 · 2025 $2,575
Food & beverage: $1,978Long term medical supply or device loan: $399Education: $198
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 8 | $476 |
| AstraZeneca Pharmaceuticals LP | 6 | $225 |
| Daiichi Sankyo Inc. | 6 | $187 |
| Merck Sharp & Dohme LLC | 5 | $163 |
| Celgene Corporation | 8 | $151 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $133 |
| Astellas Pharma US Inc | 4 | $129 |
| ABBVIE INC. | 5 | $114 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $113 |
| Janssen Biotech, Inc. | 4 | $108 |
Products named: KISQALI, KEYTRUDA, Enhertu, REBLOZYL, LYNPARZA, Nubeqa, VENCLEXTA, Padcev.
Industry payments across GA — which companies pay providers there.
